Health  Vol.8 No.14 , November 2016
Incidence and Factors Associated with the Switch to the Second Line Antiretroviral Treatment at the Ambulatory Treatment Center (CTA) in Dakar
Abstract: Introduction: Over the past years, efforts have been made to expand access to antiretroviral combinations (cART) in low-income countries. However, major concerns are noted with drug resistance emergence, as treatment failure result and need to introduce a second line treatment, more expensive and difficult to implement. The objective was to study the incidence of switch to second line, reasons for switch and risk factors using a cohort of people living with HIV in an Ambulatory Treatment Center in Dakar. Methodology: This was a cohort study of people living with HIV under cART from January 2004 to December 2013. Naive patients monitored for at least six months, regardless of their profile and regimen with baseline CD4 counts < 350 cells/mm3 were included in this study. Results: The median age of the 827 patients included was 44 [IQR = 18 - 78]. The switch to second-line treatment was observed in 72 patients (8.7%) after an average of 38.5 months of follow-up. The overall incidence rate of switch to second line of antiretroviral treatment was 1.59 per 100 persons-years. Most of changes in first-line treatment were motivated by virological failures (n = 60, 83.3%) under treatment with AZT/3TC/NVP (n = 25, 34.7%) or AZT/3TC/EFV21 (29.2%). 9.7% of switch occurred after immunological failure, 1.4% after clinical failure, 4.2% after severe toxicity and 1.4% was not documented. Predictive factors identifying failures at the end of the multivariate analysis were age < 44 years and CD4 counts below 100 cells/mm3. Conclusions: In total, CTA identified a low incidence rate of treatment failure of the first line of treatment. Associated risk factors were age < 44 years, CD4 counts below 100 cells/mm3 and high viral load at treatment initiation.
Cite this paper: Ngom-Gueye, N. , Batista, G. , Ndiaye, A. , Diouf, A. , Daye, K. , Tall, A. , Diouf, A. , Ndiaye, K. , Diop, M. , Dia, M. , Diop, C. , Gaye, A. , Ndour, C. , Seydi, M. , Gueye, L. , Diop, B. and Sow, P. (2016) Incidence and Factors Associated with the Switch to the Second Line Antiretroviral Treatment at the Ambulatory Treatment Center (CTA) in Dakar. Health, 8, 1566-1575. doi: 10.4236/health.2016.814154.

[1]   World Health Organization (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization, Geneva.

[2]   Rapport ONUSIDA sur l’épidémie mondiale de sida 2013. « ONUSIDA / JC2502/1/F » . Classification NLM: WC 503.6 (Consulté le 13/03/2014).

[3]   Rapport ONUSIDA sur l’épidémie mondiale de sida 2015.

[4]   Vézinet, F.B., Charpentier, C. and Descamps, D. (2011) Résistance aux antirétroviraux Doin édition 2011. Wolters Kluwer France 2011, 461-533.

[5]   Praag, E.V. and Vella, S. (2002) Sécurité et efficacité des traitements antirétroviraux chez l’adulte plus particulièrement en situation de ressources limités. OMS, 68 p.

[6]   Semaille, C. and Lot, F. (2011) Epidémiologie: Situation actuelle et tendances. Doin VIH édition 2011, Wolters Kluwer France, 49.

[7]   Leprêtre, A. and Ba, I. (2011) Enquête de pratiques à risque et de la prévalence des infections VIH et VHC chez les usagers de drogues injectables dans la région de Dakar. ANRS 12243 UDSEN/ICASA 2011.

[8]   Diop-Ndiaye, H., et al. (2005) Apport du laboratoire dans le diagnostic et le suivi de l’infection à VIH dans le LP. Le magazine de la pharmacie, nov.-déc., 44.

[9]   Katlama, C. and Jade, G. (2008) VIH et SIDA. Prise en charge et suivi du patient. Elsevier Masson.

[10]   Hirsch, M.S., Günthard, F.H., Schapiro, J.M., Brown-Vézinet, F., et al. (2008) Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: Recommendations of International AIDS. Clinical Infectious Diseases, 47, 266-285.

[11]   Van Heuverswyn, F., Li, Y., Neel, C., Bailes, E. and Keele, B.F. (2006) Human Immune- Deficiency Viruses: SIV Infection in Wild Gorillas. Nature, 444, 164.

[12]   Diop-Ndiaye, H., Diallo, S., Kébé, K., Diallo, F., Mboup, M., Kane, M., et al. (2008) Apport du papier filtre dans la prise en charge des patients infectés par le VIH-1 au Sénégal. Xvème ICASA 2008 abstract No. 658/SOA07.

[13]   Bartlett, J.-G. (2005) Pocket Guide to Adult HIV/AIDS Treatment Potomac Falls. Johns Hopkins University Aids Service, Baltimore, 80 p.

[14]   Erice, A., Mayers, D.L. and Strike, D.G. (1993) Primary Infection with Human Immunode- ficiency Virus Resistant Zidovidine Kind. New England Journal of Medicine, 328, 1163- 1165.

[15]   Katlama, K. (2011) Prise en charge de l’échec du traitement antirétroviral VIH édition 2011. Wolters Kluwer, Alphen aan den Rijn, 432-433.

[16]   Palombi, L., Marazzi, M., Guidotti, G., Germano, P., Buonomo, E., Scarcella, P., Altan, A., Magnano, M., Lio, S. and De Luca, A. (2009) Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability. Clinical Infectious Diseases, 48, 115-122.

[17]   Fox, M.P., Cutsem, G.V., Giddy, J., Maskew, M., Keiser, O., Prozesky, H., et al. (2012) Rates and Predictors of Failure of First-Line Antiretroviral Therapy and Switch to Second Line ART in South Africa. Journal of Acquired Immune Deficiency Syndromes, 60, 428-437.

[18]   Meriki, H.D., Tufon, K.A., Afegenwi, M.H., Nyindem, B.A., Atanga, P.N., Anong, D.N., Cho-Ngwa, F. and Nkuo Akenji, T. (2014) Immuno-Haematologic and Virologic Responses and Predictors of HIV-1 in Virologic Failure Infected Adults on First-Line in Antiretroviral Therapy in Cameroon. Infectious Diseases of Poverty, 3, 5.

[19]   Tuboi, H.S., Harrison, L.H., Sprinz, E., Albernaz, R.K. and Schechter, M. (2005) Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil. Journal of Acquired Immune Deficiency Syndromes, 40, 324-328.